Hydroelectrophoresis for Transdermal Administration of Verapamil or of Hyaluronic Acid in Peyronie's Disease: A Prospective, Open Label, Multicenter Study by Cavallini, Giorgio & Maretti, Carlo
Journal of Medical Research and Innovation Volume 2, Issue 2, e000119
Direct Access: https://jmri.org.in/jmri/article/view/119
1
Journal of Medical Research and Innovation | Volume 2 | Issue 2 | e000119
Original Article
Hydroelectrophoresis for Transdermal 
Administration of Verapamil or of Hyaluronic 
Acid in Peyronie’s Disease: A Prospective, 
Open‑Label, Multicenter Study
Carlo Maretti1, Giorgio Cavallini2*
1Department of Andrology, Centro Medico Cirm, Outpatient Clinic of Piacenza, Via Somaglia 10, 
29121 Piacenza, Italy, 2Department of Andrology, Gynepro-Medical Group, Via Tranquillo Cremona 8, 
40137 Bologna, Italy
Address for Correspondence: Giorgio Cavallini, Via Mascheraio 46, 44121 Ferrara, Italy. 
Phone: +39-0532-200847, Fax: +39-0532-1860287. E-mail: giorgiocavallini@libero.it
Abstract
Aim and Objective: This study aims to assess the efficacy of a new electromotive system for 
the transcutaneous delivery of verapamil or of hyaluronic acid to improve the symptoms of 
Peyronie’s disease (PD) in patients with a curvature deformity of <30° at the beginning of therapy. 
Methods and Materials: A total of 61 PD patients were studied. 30 were randomly assigned to receive 
verapamil 10 mg/session (Isoptin®, BGP Products, Rome-Italy) (Group 1, median age 56 years, range 
49–62), and 31 were randomly assigned to receive hyaluronic acid 8 mg/session (Sinovial®, IBSA, 
Lodi-Italy) (Group 2, median age 58 years, range 51–56). There were 10 sessions, 2 sessions/week 
for each drug. Each drug was transdermally administered using the hydroelectrophoresis technique 
and carried out using a Hydro4 and apparatus (Swiss4Med SA, Morbio Inferiore, Switzerland). With 
respect to the efficacy of the drugs studied, the end points were side effects, pain, erectile function, 
penile deviations and plaque area (cm2) before, and 3 and 6 months after drug administration. The 
differences were assessed using the Mann–Whitney rank test (unmatched groups) or using the 
Wilcoxon signed-rank test (matched groups). The differences between the groups in terms of side 
effects were assessed using the Chi-square test. Results: No significant difference emerged among 
the baseline values of the two groups. Pain, erectile function, plaque area, and penile deformity 
significantly improved in both groups after treatment, but a notably higher improvement occurred in 
the patients in whom hyaluronic acid was administered. Only a few negligible side effects occurred 
in the Group 1 patients treated with verapamil, with no significant difference between the groups.
Conclusion: Administration of both hyaluronic acid and verapamil using the Hydro4 and apparatus is 
a safe and efficient method for PD therapy.
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Introduction
Peyronie’s disease (PD) is a disorder of the 
penis characterized by plaques of fibroblast 
proliferation/fibrosis located in the tunica 
albuginea. The plaques may cause a variety 
of deformities. Pain and erectile dysfunction 
may be accompanying symptoms.[1] Originally, 
PD was regarded as a phenomenon which 
spontaneously resolved itself; however, more 
recent studies have indicated that few or 
no patients experienced disease resolution, 
whereas in a large majority of patients, the 
disease worsened.[1,2] PD might be considered a 
tumor-like disease;[3] thus, effective conservative 
therapy might be particularly welcome in the 
early stages of the disease.
Intralesional injection therapy with collagenase 
clostridium histolyticum (CCH) has been approved 
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by the U.S. Food and Drug Administration for the treatment of 
adult men with PD having palpable plaques. The severity of the 
side effects (penile hematoma and/or corporeal rupture) and 
high costs has limited the use of CCH for a curvature deformity 
of ≥30° at the beginning of therapy.[4]
This means that a number of PD patients still require non-
CCH medical therapy capable of eliminating or improving PD 
symptoms.
Intraplaque injection of hyaluronic acid recently showed a 
higher efficacy than intraplaque verapamil in improving plaque 
size and sexual function in PD patients.[5] Intraplaque injections 
are painful, may provoke hematomas, and a consistent number 
of patients have refused the treatment.[6]
These data prompted us to test a new electromotive system for 
the transcutaneous delivery of verapamil or of hyaluronic acid 
in a prospective open trial with the purpose of improving PD 
symptoms in patients with curvature deformity of <30° at the 
beginning of therapy.
Materials and Methods
Patients
This was a prospective multicenter study. All patients complaining 
of untreated/undiagnosed PD were considered for inclusion in 
the study. These patients were enrolled between January 2, 2014, 
and September 30, 2017. PD is defined by the presence of plaques 
in the tunica albuginea of the penis; the PD was diagnosed based 
on medical history, physical examination, and basal and dynamic 
duplex scanning of the penis (i.e., after intracavernosal injection 
of Alprostadil prostaglandin E1 [PGE1] 20 µg).[6]
The following laboratory assessments were carried out on 
each patient: Body mass index (body mass index = weight 
in kg/height2 in m2), blood pressure measurement, blood 
count, SGOT, SGPT, blood sugar, glycated hemoglobin, and 
prostate-specific antigen. The following assessments were 
carried out before and after drug intervention.
Objective information pertaining to the nature and magnitude 
of the patient’s penile deviation was obtained using an 
intracavernous injection (ICI) with 20 µg of Alprostadil (PGE1). 
A second injection was planned to be administered if necessary 
to achieve full erectile response, but this was never necessary 
since all patients were able to achieve full rigidity with the first 
ICI. The penile deviations were assessed on the basis of photo 
archives gathered in the outpatient clinic using the Kelami 
method[7] and calculated using a paper protractor.[8]
The following parameters were assessed before intervention: 
Pain on erection using a visual pain scale of 1–10,[9] satisfaction 
with vaginal penetration according to the international 
index of erectile dysfunction (IIEF)15 scale score,[10] penile 
deviation (in degrees),[7] and plaque size (cm2) as assessed 
using ultrasonography + ICI PGE1, 20 µg. In the case that 
more than one plaque was present, the total size and volume 
of all plaques were recorded in each patient.[2] The same 
parameters were again assessed 3 and 6 months after the end 
of the interventions.[6] The acute and chronic side effects of the 
treatments were assessed as well.
Inclusion criteria
All patients in whom PD could be diagnosed were considered 
candidates for the present study. A power analysis was carried 
out to estimate the number of observations required to have 
a reliable chance of detecting the effect sought. There are no 
formal standards for power (π); the power of our tests used 
π = 0.90 as a standard for adequacy.[11] The calculations were 
carried out using the G*Power3 program.[12]
Exclusion criteria
The exclusion criteria were the following: Refusal to participate 
in the study (12 cases), previous penile surgery or trauma 
(2 cases), pelvic surgery (6 cases), uncompensated diabetes/
hypertension (13 cases), tobacco and/or alcohol abuse 
(12 cases), penile deviation >30° (34 cases), and any previous 
treatment for PD (21 cases).[6]
Patient randomization
Randomization was carried out using an online randomizer: 
https://www.randomizer.org/. The patients were randomized 
into two groups, the first receiving verapamil 10/mg session, 
2 sessions/week for 10 weeks and the second receiving 
hyaluronic acid 8 mg/session, 2 sessions/week for 10 weeks. 
Blindness could not be insured because the mixture gel + drug 
is best used immediately after preparation, and the mixture 
was prepared by the researchers since no nurse was available. 
The majority of the papers in which verapamil was used for PD 
used 10 mg of the drug.[5,13,14]
The dosage of the hyaluronic acid was assessed on the basis 
of previous preparation tests, carried out by collecting data 
on a visual pain scale score, an IIEF15 scale score,[10] penile 
deviation (in degrees),7 and plaque size (cm2) as assessed using 
ultrasonography + ICI PGE1, 20 µg before and after hyaluronic 
acid administration. One vial/session was administered to one 
group of 10 PD patients and two vials/sessions were administered 
to another group of 10 PD patients. 2 sessions/week for 5 weeks 
were carried out for each patient. Since the visual pain scale 
score, the IIEF15 scale score, penile deviation, and plaque size 
were equally improved in all patients in both groups, a dosage of 
one hyaluronic acid vial/session was adopted.
Hydroelectrophoresis technique
Hydroelectrophoresis was performed using a Hydro4 and 
apparatus (Swiss4Med SA, Morbio Inferiore, Switzerland) 
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[Figure 1]. Briefly, hyaluronic acid 8 mg (1 ml vial) (Sinovial® Mini 
0,8%; IBSA, Lodi, Italy) or verapamil 10 mg (Isoptin®, BGP Products, 
Rome-Italy) were combined and mixed in one bottle containing 
10 ml specific gel (hydro4gel™). The mixture Hydro4 gel and drug 
were placed within a special polarization chamber (ROLL-ON). The 
apparatus was set at the appropriate level “severe PD,” and the 
polarized chamber was rolled up and down on the flaccid penis in 
correspondence of the plaque until the polarization chamber was 
empty.[15] The procedure was repeated twice a week for 5 weeks.
End points and statistical analysis
With respect to the efficacy of the drugs studied, the end points 
were side effects, pain grade, IIEF15 score, penile deviations, 
and plaque area (cm2) as assessed using ultrasonography + ICI 
PGE1, 20 µg.
The differences between the unmatched groups were 
assessed using the Mann–Whitney rank test, and the 
differences between before and after (matched groups) 
therapy were assessed using the Wilcoxon signed-rank test. 
The side effects were compared between the two groups 
using the chi2 test.[11]
Results
A total of 66 patients were eligible for participation in the study; 
32 were randomly assigned to receive verapamil (Group 1) 
and 34 hyaluronic acid (Group 2). Two patients in Group 1 
violated the protocol, and three dropped out from Group 2. 
A phone call indicated that, in 2 cases, a transfer of residence 
had occurred and, in the last case, there was a couple conflict. 
Thus, 30 patients treated with verapamil 10 mg and 31 treated 
with hyaluronic acid 8 mg were studied.
Table 1 summarizes the baseline demographic and clinical 
characteristics for each group. No significant differences 
emerged.
Table 2 summarizes the results of each study group, i.e. side 
effects, pain grade, IIEF15 score, penile deviations, and 
plaque area before and after the administration of verapamil 
or of hyaluronic acid. No significant differences emerged 
among the baseline values of the two groups. Pain score, 
IIEF 15 score, plaque area, and penile deformity notably 
improved in both groups 3 and 6 months after treatment, 
but a significantly higher improvement occurred in the 
Group 2 patients, i.e., in the patients in whom hyaluronic 
acid was administered. No significant difference existed 
between the data of Group 1 at 3 and 6 months; likewise, no 
significant difference occurred between the data of Group 2 
at 3 and 6 months. Only a few negligible acute side effects 
occurred in the Group 1 patients treated with verapamil, 
with no significant difference between the groups. No 
chronic side effects occurred in either group.
Figure 1: Complete figure of the Hydro4 and apparatus 
(Swiss4Med SA, Morbio Inferiore, Switzerland). *The 
apparatus was set at the appropriate level “Severe 
Peyronie’s Disease.” A white bottle contained hyaluronic acid 
8 mg (Sinovial® Mini 0,8 %; IBSA, Lodi, Italy) or verapamil 
10 mg (Isoptin®, BGP Products, Rome‑Italy) + 10 ml specific 
gel (hydro4gel™). The white bottle is attached to the special 
polarization chamber (ROLL‑ON). The polarized chamber was 
rolled up and down on the flaccid penis in correspondence 
of the plaque until the polarization chamber and the bottle 
were empty
Table 1: Baseline demographic and clinical characteristics for each group participating in the study
Group 1: 30 patients treated with 
10 hydroelectrophoretic rounds, 
each round carried out with 
verapamil 10 mg
Group 2: 31 patients treated with 
10 hydroelectrophoretic rounds, 
each round carried out with 
hyaluronic acid 8 mg
P value
Age in years 56 (49–62) 58 (51–56) 0.345
Mean BMI in Kg/m2 24 (20–28) 23.5 (20–27) 0.310
Compensated 
hypertension (%)
12 (40) 11 (35.5) 0.207
Dupuytren’s contracture (%) 0 0 Not tested
Compensated diabetes (%) 6 (20) 7 (22.6) 0.434
*Data are shown as median values, and the ranges are in parentheses; the difference between the median values was examined using the Mann–Whitney rank test. Differences 
between percentual data were examined using the Chi-square test. No significant difference ever emerged. BMI: Body mass index
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Discussion
The end points of this study were to ascertain whether 
hydroelectrophoresis could be an efficient and safe system for 
administering drugs for PD. As a matter of fact, the transdermal 
administration of both hyaluronic acid and verapamil using a 
Hydro4 and apparatus led to an improvement in PD symptoms, 
and hyaluronic acid proved to be more efficient than verapamil 
in both reducing curvature, pain and plaque area, and in 
improving erectile function. The fact that only a few negligible 
acute side effects occurred prompted us to further sustain that 
the Hydro4 and apparatus is a safe system for transdermally 
administering drugs.
Verapamil and hyaluronic acid display a number of 
characteristics which might be useful in resolving PD 
symptoms. Hyaluronic acid decreases the production of 
the pro-inflammatory cytokine tumor necrosis factor-α, 
prevents apoptosis, increases cell survival, prevents fibrosis, 
reduces inflammation and heterophile infiltration, improves 
neoangiogenesis, and reduces pain and burning sensation.[16]
Verapamil alters the fibroblast production of extracellular matrix 
macromolecules, inhibiting exocytosis of the extracellular 
matrix; it inhibits the expression of collagen and increases the 
proteolytic activity of collagenase, thereby enhancing matrix 
remodeling by human fibroblasts. It also affects the cytokine 
expression associated with the early phases of wound healing 
and inflammation and possesses a profound inhibitory effect 
on cell proliferation.[17]
Limitations
This paper has three biases
The first was that no placebo was used. As a matter of fact, 
it was quite impossible to find a placebo substance for PD 
because even the intralesional administration of a physiologic 
solution significantly reduces plaque size.[17-19]
The second was that the authors were unblinded to the drug 
used. However, pain and sexual function assessment was 
carried out by administering a validated questionnaire to the 
patients; thus, the results of the therapies were evaluated by 
the patients themselves. Additional plaque area and penile 
deformity assessments were carried out using objective 
methods (photography, dynamic duplex, and paper protractor) 
to reduce the influence of the authors as much as possible.
The third was that no branch made up of untreated patients 
was tested. Currently, the Helsinki declaration of human rights 
(http://www.partecipasalute.it/cms/files/Dichiarazione%20
di%20Helsinki.pdf) precludes the possibility of not treating 
patients when they are recognized to be affected by a 
progressive disease, and PD is a progressive disease in the 
majority of the cases.[1,2]Ta
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Conclusion
As a conclusion, hydroelectrophoresis performed with a Hydro4 
and apparatus is a safe and efficient method for delivering 
transcutaneous drugs to relieve PD symptoms.
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